EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Catalpol reverses doxorubicin-induced cognitive decline, neuroinflammation, and restores synaptic integrity

Anh C D Le, Sanad M El-Khatib, Brandon M Tran, Fan-Ying Chan, Alexandre Chan, Munjal M Acharya

Phytomedicine · 2026

DOI: 10.1016/j.phymed.2026.158372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026. Verfasst von Anh C D Le und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Neurobiology, University of California Irvine, USA. Hauptthemen laut MEDLINE: Doxorubicin, Iridoid Glucosides, Neuroinflammatory Diseases, Neuroprotective Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, University of California Irvine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cancer therapy-related cognitive impairments (CRCI) are detrimental for millions of cancer survivors. Chemotherapy induces neuroinflammation and reduces synaptic integrity, contributing to CRCI. Our past pre-clinical animal studies showed synaptic loss, including postsynaptic density protein 95 (PSD-95) and dynamin-1, that were associated with CRCI. Our human observational data showed reduced plasma dynamin-1 in breast cancer patients receiving chemotherapy. Since these proteins promote synaptic trafficking and plasticity that contribute to cognitive function, augmenting and protecting synaptic integrity represents a viable solution to reverse CRCI. Catalpol, a phytochemical, isolated from Rehmannia glutinosa (Gaertn.) Libosch. ex DC. plant root, has been shown to increase PSD-95 and dynamin-1, and reduce microglial activation in the injured brains. PURPOSE: This study tested the neuroprotective impact of oral catalpol treatment in the mouse model of CRCI. METHODS: Adult wild-type mice received either vehicle or chronic chemotherapy, doxorubicin (Adriamycin®, 3 mg/kg, intraperitoneal) once weekly for four weeks. 72 h after the last Adriamycin injection, mice were treated with catalpol (0.5 mg/ml corresponding to 50 mg/kg) for one month in drinking water (in addition to 50 mg/kg daily injections for the first 6 days), followed by cognitive function testing. RESULTS: Administration of catalpol to Adriamycin-exposed mice significantly improved cognitive performance in the spatial recognition memory task. Hippocampal tissue analysis revealed that catalpol significantly reduced microglial activation and prevented loss of synaptic machinery proteins, including dynamin-1 and PSD-95, in the Adriamycin-exposed brains. Catalpol also restored hippocampal neurogenesis and neuronal plasticity-related cFos. CONCLUSION: This data provides pre-clinical evidence of the feasibility of oral administration of catalpol as a phytopharmaceutical candidate for CRCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinIridoid GlucosidesNeuroinflammatory DiseasesNeuroprotective AgentsChemotherapy-Related Cognitive ImpairmentCognitive DysfunctionAnimalsMiceRehmanniaMice, Inbred C57BLDisks Large Homolog 4 ProteinSynapsesHippocampusMicrogliaDisease Models, AnimalMaleCognitive EnhancementNeuronal Plasticity

Stichwörter der Autor:innen

CatalpolChemotherapyCognitive functionDynamin-1NeuroinflammationSynaptic plasticity

Substanzen

catalpolDoxorubicinIridoid GlucosidesNeuroprotective AgentsDisks Large Homolog 4 Protein

Autor:innen und Institutionen

  • Department of Anatomy and Neurobiology, University of California Irvine, USA.
  • Department of Clinical Pharmacy Practice, University of California Irvine, USA.
  • Department of Clinical Pharmacy Practice, University of California Irvine, USA. Electronic address: a.chan@uci.edu.
  • Department of Anatomy and Neurobiology, University of California Irvine, USA; Department of Radiation Oncology, University of California Irvine, USA. Electronic address: macharya@uci.edu.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • University of California Irvine

Zitieren

APA

Le, A. C. D., El-Khatib, S. M., Tran, B. M., Chan, F. Y., Chan, A., & Acharya, M. M. (2026). Catalpol reverses doxorubicin-induced cognitive decline, neuroinflammation, and restores synaptic integrity. Phytomedicine. https://doi.org/10.1016/j.phymed.2026.158372

Vancouver

Le ACD, El-Khatib SM, Tran BM, Chan FY, Chan A, Acharya MM. Catalpol reverses doxorubicin-induced cognitive decline, neuroinflammation, and restores synaptic integrity. Phytomedicine. 2026. doi:10.1016/j.phymed.2026.158372

BibTeX
@article{Le2026,
  author = {Le, Anh C D and El-Khatib, Sanad M and Tran, Brandon M and Chan, Fan-Ying and Chan, Alexandre and Acharya, Munjal M},
  title = {Catalpol reverses doxorubicin-induced cognitive decline, neuroinflammation, and restores synaptic integrity},
  journal = {Phytomedicine},
  year = {2026},
  doi = {10.1016/j.phymed.2026.158372}
}
Kostenlos starten →